Asad Haider
Stock Analyst at Goldman Sachs
(2.80)
# 1,645
Out of 5,182 analysts
15
Total ratings
71.43%
Success rate
18.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Upgrades: Buy | $115 → $142 | $99.35 | +42.93% | 2 | Jan 16, 2026 | |
| JNJ Johnson & Johnson | Maintains: Buy | $213 → $240 | $224.20 | +7.05% | 3 | Dec 19, 2025 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Neutral | $30 → $37 | $29.86 | +23.91% | 2 | Dec 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $51 → $57 | $57.38 | -0.66% | 2 | Dec 2, 2025 | |
| INVA Innoviva | Initiates: Sell | $17 | $22.99 | -26.05% | 1 | Sep 30, 2025 | |
| RPRX Royalty Pharma | Initiates: Buy | $42 | $50.20 | -16.33% | 1 | Sep 30, 2025 | |
| PCVX Vaxcyte | Initiates: Neutral | $38 | $58.49 | -35.03% | 1 | Sep 12, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $892 → $888 | $967.93 | -8.26% | 1 | Apr 8, 2025 | |
| ABBV AbbVie | Assumes: Neutral | $194 | $208.16 | -6.80% | 1 | Apr 8, 2025 | |
| PFE Pfizer | Downgrades: Neutral | $32 → $25 | $26.30 | -4.94% | 1 | Apr 8, 2025 |
BioNTech SE
Jan 16, 2026
Upgrades: Buy
Price Target: $115 → $142
Current: $99.35
Upside: +42.93%
Johnson & Johnson
Dec 19, 2025
Maintains: Buy
Price Target: $213 → $240
Current: $224.20
Upside: +7.05%
NewAmsterdam Pharma Company
Dec 2, 2025
Maintains: Neutral
Price Target: $30 → $37
Current: $29.86
Upside: +23.91%
Bristol-Myers Squibb Company
Dec 2, 2025
Maintains: Neutral
Price Target: $51 → $57
Current: $57.38
Upside: -0.66%
Innoviva
Sep 30, 2025
Initiates: Sell
Price Target: $17
Current: $22.99
Upside: -26.05%
Royalty Pharma
Sep 30, 2025
Initiates: Buy
Price Target: $42
Current: $50.20
Upside: -16.33%
Vaxcyte
Sep 12, 2025
Initiates: Neutral
Price Target: $38
Current: $58.49
Upside: -35.03%
Eli Lilly and Company
Apr 8, 2025
Upgrades: Buy
Price Target: $892 → $888
Current: $967.93
Upside: -8.26%
AbbVie
Apr 8, 2025
Assumes: Neutral
Price Target: $194
Current: $208.16
Upside: -6.80%
Pfizer
Apr 8, 2025
Downgrades: Neutral
Price Target: $32 → $25
Current: $26.30
Upside: -4.94%